A detailed history of Vanguard Group Inc transactions in Humacyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,019,681 shares of HUMA stock, worth $19.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,019,681
Previous 3,123,266 28.7%
Holding current value
$19.3 Million
Previous $8.87 Million 40.94%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.57 - $4.84 $2.3 Million - $4.34 Million
896,415 Added 28.7%
4,019,681 $12.5 Million
Q4 2023

Feb 14, 2024

BUY
$1.99 - $3.12 $207,555 - $325,412
104,299 Added 3.45%
3,123,266 $8.87 Million
Q3 2023

Nov 14, 2023

BUY
$2.75 - $4.48 $138,410 - $225,482
50,331 Added 1.7%
3,018,967 $8.85 Million
Q2 2023

Aug 14, 2023

BUY
$2.86 - $4.97 $6,746 - $11,724
2,359 Added 0.08%
2,968,636 $8.49 Million
Q1 2023

May 15, 2023

BUY
$2.11 - $3.25 $255,339 - $393,295
121,014 Added 4.25%
2,966,277 $9.17 Million
Q4 2022

Feb 10, 2023

BUY
$2.02 - $3.62 $351,762 - $630,386
174,140 Added 6.52%
2,845,263 $6 Million
Q3 2022

Nov 14, 2022

SELL
$1.22 - $5.14 $3,516 - $14,813
-2,882 Reduced 0.11%
2,671,123 $8.71 Million
Q2 2022

Aug 12, 2022

BUY
$3.21 - $7.86 $808,871 - $1.98 Million
251,985 Added 10.4%
2,674,005 $8.58 Million
Q1 2022

May 13, 2022

BUY
$4.65 - $7.4 $5.83 Million - $9.28 Million
1,253,788 Added 107.32%
2,422,020 $17.1 Million
Q4 2021

Feb 14, 2022

BUY
$7.25 - $11.6 $6.37 Million - $10.2 Million
878,123 Added 302.69%
1,168,232 $8.47 Million
Q3 2021

Nov 12, 2021

BUY
$9.21 - $16.99 $2.67 Million - $4.93 Million
290,109 New
290,109 $3.37 Million

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $494M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.